Agnholt JS - Search Results

1

Discontinuation of Infliximab Therapy in Patients with Crohn's Disease.

Buhl S, Steenholdt C, Brynskov J, Christensen KR, Dorn-Rasmussen M, Thomsen OØ, Bendtzen K, Klausen TW, Dahlerup JF, Thorsgaard N, Jahnsen J, Molazahi A, Pedersen N, Kjeldsen J, Almer S, Dahl EE, Vind I, Cannon AG, Marsal J, Sipponen T, Agnholt JS, Kievit HAL, Aure SL, Martinsen L, Meisner S, Hansen JM, Ainsworth MA. Buhl S, et al. Among authors: agnholt js. NEJM Evid. 2022 Aug;1(8):EVIDoa2200061. doi: 10.1056/EVIDoa2200061. Epub 2022 Jun 14. NEJM Evid. 2022. PMID: 38319804 Clinical Trial.

2

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab.

Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Bendix M, et al. Nutrients. 2020 Nov 30;12(12):3699. doi: 10.3390/nu12123699. Nutrients. 2020. PMID: 33266022 Free PMC article. Clinical Trial.

3

Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.

Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF. Hvas CL, et al. Autoimmunity. 2010 Jun;43(4):325-33. doi: 10.3109/08916930903509064. Autoimmunity. 2010. PMID: 20298123

4

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up.

Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Bendix M, et al. Nutrients. 2021 Mar 26;13(4):1083. doi: 10.3390/nu13041083. Nutrients. 2021. PMID: 33810258 Free PMC article.

5

The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-α therapy.

Sandahl TD, Kelsen J, Dige A, Dahlerup JF, Agnholt J, Hvas CL, Thiel S. Sandahl TD, et al. J Crohns Colitis. 2014 Jun;8(6):521-8. doi: 10.1016/j.crohns.2013.11.007. Epub 2013 Nov 28. J Crohns Colitis. 2014. PMID: 24291022

6

The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.

Agnholt J, Dahlerup JF, Kaltoft K. Agnholt J, et al. Cytokine. 2003 Aug 7;23(3):76-85. doi: 10.1016/s1043-4666(03)00201-1. Cytokine. 2003. PMID: 12906870

7

Active Crohn's disease is associated with low vitamin D levels.

Jørgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF. Jørgensen SP, et al. J Crohns Colitis. 2013 Nov;7(10):e407-13. doi: 10.1016/j.crohns.2013.01.012. Epub 2013 Feb 9. J Crohns Colitis. 2013. PMID: 23403039

8

Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.

Agnholt J, Dahlerup JF, Buntzen S, Tøttrup A, Nielsen SL, Lundorf E. Agnholt J, et al. Aliment Pharmacol Ther. 2003 Mar 1;17(5):703-10. doi: 10.1046/j.1365-2036.2003.01487.x. Aliment Pharmacol Ther. 2003. PMID: 12641520 Free article.

9

T-cell vaccination in Crohn's disease: principles and presentation of the first two cases.

Agnholt J, Kaltoft K, Jakobsen NO, Dahlerup JF. Agnholt J, et al. Cytokines Cell Mol Ther. 2002;7(3):117-23. doi: 10.1080/13684730310000130. Cytokines Cell Mol Ther. 2002. PMID: 12850811

10

Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.

Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF. Agnholt J, et al. Eur J Gastroenterol Hepatol. 2004 Jul;16(7):649-55. doi: 10.1097/01.meg.0000108344.41221.8b. Eur J Gastroenterol Hepatol. 2004. PMID: 15201577

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page